HLA-G and plasma cell myeloma: In this regard, enhanced sHLA-G (i.e., HLA-G5 and shed HLA-G1) plasma levels have been described in B cell malignancies, such as multiple myeloma, non-Hodgkin B-lymphoma, and B-CLL [35, 36].